Charlottesville, VA – January 31 2012 – HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, announced today the appointment of Robert A. Figler, Ph.D., as scientific director.
HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that it has been awarded up to $4.3 million in a Phase II Small Business Innovation Research (SBIR) grant award from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, announced today the appointment of Gerald Fisher, Ph.D., former Senior Vice President of Drug Safety and Metabolism at Wyeth Pharmaceuticals, to its Scientific Advisory Board.
HemoShear, LLC, is pleased to announce that it has received a Phase I Small Business Innovation Research (SBIR) grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).
HemoShear announced today the appointments of Ajit Dash, M.D., Ph.D., as Scientific Director, Liver Surrogate Systems, and Wendy L. Yarno as Chief Marketing Officer.
Grants Support Development of Additional Systems to Improve Productivity of Pharmaceutical R&D
This patent covers HemoShear's core technology which replicates the biology of healthy and diseased human organ systems by applying physiologically-relevant hemodynamic (blood flow) forces and other conditions to organ-specific primary cells.
Ruffolo and Batchelor Bring Strong Industry Drug Development Expertise
Results Expected to Lead to Development of Safer, More Effective Treatments of Human Artery Disease
Findings Published in a Journal of the American Heart Association
Human Surrogate Model will be used to study the disease's inflammatory onset.
American Physiological Society Honors HemoShear Co-Founder and Vice-President of Research and Development.
Transplant specialist to advise HemoShear in developing advanced models of the human liver for discovery of new drug candidates and study of liver diseases.
HemoShear, LLC, a developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds in the laboratory recently completed $5 million in angel equity financings. The funds will be used to launch commercial applications of its human artery model and to develop a human surrogate liver model for discovery and testing of new drug compounds.
HemoShear, LLC, a developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds in the laboratory, today announced that John L. Brooks III has joined its Board of Managers.